Who We Are
EMIG is a multi-stakeholder network and trade industry association that represents the interests of the full span of life sciences companies in the UK. Our industry Members, range from new business start-ups focused on R&D, through to well-established companies delivering a wide range of essential medicines to patients.
Our Members
EMIG has over 300 Member Companies and organisations – including Associate Members drawn from academia, patient organisations, learned societies and companies providing essential support services to the Life Sciences ecosystem. Collectively we represent the breadth of the health and medicines ecosystem, from research, clinical development and manufacturing, through to patient charities, research policy organisations and academic institutions. This means EMIG has become a platform for greater knowledge and ideas exchange.
EMIG Members List
A
Academy of Medical Sciences
Accord Healthcare
Actavis
Action Duchenne
Action on Hearing Loss
Addex Therapeutics
Aegerion Pharma
Aguettant UK Ltd
Akcea Therapeutics
Alan Pharmaceuticals
Alexion Pharmaceuticals
Alison Campbell Associates
Alkaptonuria Society
Allergan Ltd
Alliance Pharma plc
Altacor Pharma Ltd
Alturix
Alveo Solutions
Amgen
Amryt Pharma
Amyloidosis Research Consortium
Andrew Carr Associates
Apodi
ApoPharma Inc
Applied Driving Techniques
Aqix
Aquila Biolabs
Arkivum
Ashfield Healthcare
Aspire Pharma
Association of Medical Research Charities
Astellas
Atnahs
Avitus Group
Axis Healthcare Consulting
B
Baxter
Besins Healthcare
BGP Products Ltd (Mylan)
Bial Pharma
BioCryst Pharmaceuticals
Biofilm
Biomarin
Bionest
Bionical
Biotest UK Ltd
Biotherapy Services Ltd
Birmingham Health Partners
Bloom Health Ltd
Blue Chip Healthcare
Bob Hackett Training Consultancy
Boom! Healthcare Communications
Brabant Pharma
Brandcast Health
Britannia Pharmaceuticals
British Liver Trust
Business France
C
C3 Collaborating for Health
C&C Group
C&D Data
Cambridge Enterprise
Cambridge Healthcare
Cambridge Rare Disease Network
Campbell Charles Associates (2000) Ltd
Cancer52
Cancer Research UK
capture1
Cegedim
Celdra Ltd
Celgene
Cello Health Corporate Affairs
Certara
CG Pharma
Chantrey Vellacott
Chapper Healthcare
Charlwood Pharma
Cheemia Ltd
Chiesi Pharmaceuticals
Clarity Pharma Ltd
Clinigen
Clinimed
Cognicept
Cognite
Conseptua Training & Consulting
Costello Medical
Consilient Health
Contura
Corbett Keeling
Creo Pharma
CSL Behring
Curium Pharma
Custom Healthcare
Cystic Fibrosis Trust
D
Daiichi Sankyo
Daniel and Daisy Novel Therapeutics Ltd
Datapharm
Davies Consulting
Dee Pharmaceuticals Ltd
Derma UK
Dermal Laboratories Ltd
Dermapharm
Desitin Pharma
Diabetes Professional Care
Dierks & Company
Discovery Pharmaceuticals
Draper & Dash
Dr Falk Pharma UK Ltd
Dr Reddy’s
E
Equa Pharma Ltd
ESMS Global – Emergency Scientific & Medical Services
Ethypharm
European Association for Logistics and Transportation in Healthcare
European Confederation of Pharmaceutical Entrepreneurs
EUSA Pharma
Eventum Partners
Everything Genetic
Experimental Cancer Medicine Centres
F
Ferring Pharmaceuticals Ltd
Fight for Sight
Findacure
Firefly
Fish Pharma Recruitment
Flexipharm Austrading
Flynn Pharma
Four Public Affairs
FTI Consulting
Funding Neuro
Future Thinking
G
Galapagos
Galderma (UK) Ltd
GBT
Gedeon Richter
Genetic Alliance
Genetic Disorders UK
Genomics England
Gilead Sciences Int ltd
Grey Bear Consultancy
Grifols UK Ltd
Guerbet Laboratories
GW Pharmaceuticals
H
Havas M&C
Healthcare at Home
healx
Healthcare Business Managers Group
Helm Pharmaceuticals
Henry Schein UK Holdings Ltd
HFA Healthcare Products Ltd
Horizon Pharma
HRA Pharma Ltd
Huron
I
ICL Therapeutics
Idea Pharma
Illustratum
Imperial College London
IQVIA
Incyte
Intercept Pharmaceuticals
International Health Partners
Intrapharm Laboratories
IQ Pharma
J
Jazz Pharmaceuticals
Jenson R+
K
Kidney Research UK
King’s Health Partners
Kowa Research Europe Ltd
Kyowa Kirin
L
Leadiant Biosciences
Leicester School of Pharmacy, De Montfort University
Leukaemia CARE
LFB Biopharmaceuticals
Lightning-API Ltd
Logixx Pharma Ltd
Lucane Pharma SA
M
Making Pharmaceuticals
Map BioPharma
MASTA
MaimoniDex RA Ltd/MaimoniDex (UK) Ltd
MedDay Pharmaceuticals
Medical Need Europe
Medical Research Council Technology
Merz Pharma Ltd
Metabolic Support UK
Mibe Pharma Ltd
Moorfields Pharmaceuticals
Morningside Healthcare
MORPh Consultancy Ltd
Muscular Dystrophy Campaign
Myeloma UK
Myoderm
N
Nanogenics Ltd
National Clinical Homecare Association
NHS Confederation
National Services for Health Improvement
National Voices
Neoceuticals
Neonavitas
Neubourg Pharma UK
NEURAXPHARM
Network Pharma
NHS Alliance
Nordic Pharma
Norgine
North 51
Novartis Gene Therapies
O
OBN
Octapharma
Open Health
Orphan Insight Ltd
OUTiCO Ltd
P
ParaPharm Development
Patients Direct
Penlan Healthcare Ltd
Pharma Solutions
Pharmacloud
Pharmaceutical Marketing Society
PharmacoMedics
Pharmexx
Pharmiweb Solutions
pi2 Health
Pierre Fabre
Pinsent Masons
Piramal
Polycystic Kidney Disease Charity
Plymouth University
Portola Pharmaceuticals
Precision Medicine Catapult
Premier Research
Present Value Ltd
Primius Lab Ltd
Promedim
Q
Queen Mary University of London
R
Rapidscan Pharma Solutions
Raptor Pharmaceuticals Europe
Rare Disease UK
Rarer Cancers Foundation
Rare Revolution Magazine
Real Regulatory
Ridge Pharma
Roboleo & Co
Rocket Science Consultancy
Rouse
Royal Society of Biology
S
Sandoz
Santhera Pharmaceuticals
Sanofi Genzyme
Sciensus Ltd
Seek Pharma
Senzer
Servier Laboratories Ltd
Sigma-Tau Pharmaceuticals
Soar Beyond
Solaris Health
Spargonet
Spark Health
SpePharm
Spirit Healthcare
STD Pharmaceuticals
Star Medical
Stirling Anglian Pharmaceuticals
Stratagem+ Ltd
Structural Genomics Consortium, Oxford University
Substipharm
SwedenBIO
Swedish Orphan Biovitrum Ltd
T
Takeda
Talentmark
Tangent90
Tanner Pharma
Targeted Solutions Ltd
Technology4Events Ltd
Teijin Pharma
Tetris Pharma
Teva
The Alkaptonuria Society
The Healthcare Partnership
The Institute of Cancer Research
The M.E. Trust
Thea Pharmaceuticals
The Medical Research Network
The Royal Osteoporosis Society
The Urology Company Ltd
Thornton & Ross Pharmaceuticals
Tillotts Pharma (UK) Ltd
Tilray
Typharm Ltd
U
UCL Business
UCL Partners
UK Innovation Forum
Uniphar
Universities UK
University of Bristol
University of Exeter
University of Leicester
University of Manchester
University of Southampton, Research & Innovation Services
University of Wolverhampton
V
Valuebase
V Pharma
Vectura
Veale Wasbrough Vizards
Vidant Pharma
Vifor Pharma
VISUfarma
Vivacity Advertising
W
Wave Data Ltd
WEP Clinical
Whately-Smith Ltd
Williams Medical Supplies
Wilmington Healthcare
Wyndham Hynds Ltd
X
Xiota
What We Do
We host an annual Parliamentary Dinner as well as Quarterly Meetings in central London, typically attended by over 100 Members. On request, we connect companies with other Members who can provide practical assistance e.g. in licensing and outsourcing opportunities.
EMIG enables members to network and meet like-minded professionals who experience the same industry challenges
All our Special Interest Groups meet three times a year in central London and any member is entitled to join.
EMIG represents its Members on the issues directly affecting their businesses.
How we work
EMIG Steering Group
-
The Steering Group oversees the operation of the organisation, its priorities and work programme, and is led by Leslie Galloway. We are unique among life sciences trade associations in that we have a patient organisation representative on the Group.
-
Members of the EMIG Steering Group include our Chairman, Leslie Galloway, Vice Chairman, Abid Karim, Legal Advisor Paul Ranson, Eric Low, who started Myeloma UK, and now contributes to patient access to medicines via Eric Low Consulting, and 12 heads of Member Companies.
-
Our policy is ‘One Member – One Vote’. This means our work programme can be developed and approved by the full breadth of our Membership, with full transparency.
EMIG Projects & Collaborations
-
EMIG is committed to collaborative working with academia, charities, patient groups and research-focused bodies to encourage scientific research and innovation in the UK. Better Research for Better Outcomes is an initiative joining up stakeholders from these communities to lead a work programme that seeks to develop a UK value framework for better research.
-
Through EMIG’s Medical Directors Forum, we enable all types of Member organisations to work for collaborative advantage, to encourage the sharing of pre-competitive data and best practices, and to ensure that knowledge, innovation and enterprise can be effectively curated with the life sciences sector in the UK.
-
EMIG works alongside our trade association colleagues in life sciences on shared issues.
Special Interest Groups
We have a number of SIGs to reflect the differing priorities and needs of the myriad roles that make a successful biopharmaceutical company. SIGs meet quarterly and inform EMIG positions on a wide range of issues, from regulation and research, to pricing and orphan diseases.
Each Group has a Chair and the Group determines the content of each meeting agenda.
All our SIGs meet quarterly, mostly in central London, and any Member is entitled to join. Policy proposals made by the SIGs are reviewed by the EMIG Steering Group, and ratified by the Membership, often at our Quarterly Meetings throughout the year.
See how our Special Interest Groups can benefit you:
EMIG has the following Special Interest Groups:
Business Development
The EMIG Business Development Group is a networking meeting for those members focussed on building their business by M&A, licensing, partnering and novel in market strategies.
The Group meets quarterly at the Manor, Weston on the Green, Oxfordshire. Every meeting starts with a networking lunch followed by an afternoon of interesting content which might typically include:
- a member company showcasing their business and strategy
- case histories of deals completed
- contemporary topics affecting the marketplace
- professional advice & services from member companies.
The meeting is followed by a networking dinner.
The Group was established in 2010 and has become a firm fixture on the UK business development calendar.
Digital
The EMIG Digital Health Group is a networking meeting for those members focused on understanding the latest developments in digital health and going “beyond the pill”.
The Group meets 3 times a year, typically in London. Every meeting starts with a networking coffee followed by a few hours of interesting content which might typically include presentations by:
- members on what they are doing in digital health
- digital health companies
- other relevant stakeholders e.g., NHS Digital, digitalhealth.london, MHRA etc.
Finance
The Finance Group meets on a quarterly basis to learn, debate and help shape the critical topics and issues affecting the industry from a finance perspective.
The Finance Group is focussed on offering members an opportunity to:
- network and meet like-minded professionals who experience the same industry challenges
- gain knowledge and learn, with presentations and talks that are focussed on the finance community’s needs’
- have a sounding board for practical issues and give support to others
- share experiences and explore different approaches.
HR
The EMIG HR Group meets four times per year in London and provides a great opportunity for HR professionals to come together for networking and the exchange and sharing of information and new ideas.
We regularly feature external speakers and Members have the opportunity to agree topics to be explored at future meetings. We also offer Members the opportunity to:
- gain knowledge and learn, with presentations and talks that are focussed on Members’ needs
- network and meet like-minded professionals who experience the same industry challenges
- debate important topics
- provide a sounding board for practical issues and give support to others.
Compliance
Current issues being looked at by the Group include pricing and reimbursement transparency, data protection, medical devices approval and safety, biosimilars and rare diseases. This is in addition to other changes that impact on companies more widely such as competition law, bribery and corruption, tax and patents and other intellectual property.
So that EMIG members can keep up to date with changes that most affect their business Pinsent Masons LLP and Alexander Natz, Secretary-General of EUCOPE have agreed to establish and run a quarterly EU and Legal Issues Special Interest Group. The aim will be to review recent and forthcoming changes and discuss in depth issues where Government consultation is ongoing or where urgent action may be necessary.
Meetings will be held at Pinsent Masons’ offices in the City. Further details including the agenda will be sent out by way of a reminder nearer the time.
Market Access
The Market Access Group aims to:
-
reduce the hurdles to uptake in the UK and enable innovative products to reach patients in a timely manner
-
identify cost-effective solutions to market access challenges
-
work with government and officials to communicate new developments
-
understand the impact on the varied range of EMIG member companies (biotechs to mature companies) of gaining market access in the UK.
Medical Directors’ Forum
The EMIG Medical Directors’ Forum aims:
-
to promote a scientific and medical research policy and operating environment that supports the growth and sustainability of small to medium-sized pharmaceutical companies
-
to identify and access new partnership opportunities for technology development with academia and the NHS
-
to build an innovative open platform for knowledge exchange and collaboration between diverse life sciences organisations.
EU and Legal Issues Group
So that EMIG members can keep up to date with changes that most affect their business Pinsent Masons LLP and Alexander Natz, Secretary-General of EUCOPE run a quarterly EU and Legal Issues Special Interest Group. The aim is to review recent and forthcoming changes and discuss in depth issues where Government consultation is ongoing or where urgent action may be necessary.
Regulatory
The EMIG Regulatory Group holds regular information sharing and networking meetings for those members working in Regulatory Affairs, related disciplines or those with an interest in understanding more about current challenges impacting the industry.
The Group meets at least three time a year in London. Each meeting focuses on current hot topics and takes the form of presentations and/or group discussions. External experts and Regulatory Authority personnel are often invited as appropriate. Events are a valuable networking opportunity, with time allocated at the start of each session for informal networking.
In addition, the EMIG Regulatory Group takes the lead on two key MHRA meetings for our membership:
- cross trade meeting
- bi-lateral meeting.
EMIG Northern Ireland Group
The Northern Ireland Group provide a platform for engagement with the NHS and other stakeholders in Northern Ireland and enable networking and shared learning across Member companies.
A political update is presented at each meeting.
EMIG Scotland Group
The EMIG Scotland Group focuses on issues including:
-
co-operation with the Scottish Lifesciences Association
-
engagement with SMC
-
SMC position on uptake and clinical standards
-
CEL 17 and the question of how it needs to be implemented by Health Boards.
EMIG Wales Group
The EMIG Wales Group was established to:
-
provide a voice for members in Wales
-
build relations with the All Wales Medicines Strategy Group and with key stakeholders in the Welsh Assembly
-
engage with Bioinnovation Wales.
EMIG’s mission
“We work closely with government, regulators, HTA bodies, academia, medical research organisations and the NHS to advance patient access to the most effective and innovative medicines; to promote the UK as an attractive environment for research and investment; and to enhance our Members’ ability to operate effectively.”
Our Values
In pursuing our mission we strive to be:
-
Patient-centred
-
Accountable
-
Results focused
-
Collaborative
-
Innovative
-
Evidence-based
-
Open